Exabis Library
Welcome to the e-CCO Library!
P460: A Real-World Picture of Adverse Drug Reactions in Inflammatory Bowel Disease
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P460: Biomarkers reflecting extracellular matrix turnover and inflammation can be used to monitor disease activity and treatment response in patients with Crohn’s disease undergoing infliximab induction therapy
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P460: Early use of therapeutic drug monitoring to individualize infliximab therapy in paediatric IBD: a multicentre prospective COHORT study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P460: Effect of fertility treatment on inflammatory bowel disease outcomes
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P460: Efficacy of ustekinumab in patients with anti-TNF refractory Crohn’s disease: data from a real-world study in Brazil
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P460: Impact of anti-TNFα exposure during pregnancy for maternal inflammatory bowel disease on serologic response to vaccination of exposed children
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P460: Preoperative nutrition supplementation may prevent one-year endoscopic recurrence in Crohn's disease patients
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P461 Intolerance to 5-aminosalicylate is a risk of poor prognosis in ulcerative colitis patients
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P461: Clinical benefit of adalimumab after surgery in the treatment of complex perianal Crohn’s disease: a tertiary referral centre experience
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P461: Comparison of efficacy of different oral 5-aminosalicylic acid doses for maintenance of remission in ulcerative colitis: a systematic review and meta-analysis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P461: COVID-19 outcomes in patients receiving anti-TNF treatments: A systematic review and meta-analysis
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P461: Endoscopic features for loss of response in patients with Crohn’s disease who were treated with infliximab by top-down strategy
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P461: Post-marketing safety experience of vedolizumab in older patients with inflammatory bowel disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P461: Rapid response to appendectomy in the majority of patients with refractory Ulcerative Colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P461: Vedolizumab Dose Escalation in a Real-World Cohort of IBD Patients
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P462 Efficacy of ustekinumab for the prevention of postoperative recurrence in crohn’s disease. Data from clinical practice from the eneida registry
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P462: Adalimumab improves treatment satisfaction with medication and work productivity amongst patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P462: Delayed Responders with Ustekinumab in Ulcerative Colitis Have Increased Inflammatory Burden but Similar Long-term Outcomes as Early Responders
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P462: Dietary restrictions on inflammatory bowel disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P462: Impact of teduglutide, a GLP-2 agonist, on inflammatory bowel disease-associated short bowel syndrome: a tertiary single-center study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM